Neuberger Berman Group’s Dr. Reddy's Laboratories RDY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $666K | Sell |
45,951
-48,591
| -51% | -$656K | ﹤0.01% | 1688 |
|
|
2026
Q1 | $1.3M | Sell |
94,542
-2,049
| -2% | -$28.5K | ﹤0.01% | 1319 |
|
|
2025
Q4 | $1.36M | Sell |
96,591
-28,468
| -23% | -$399K | ﹤0.01% | 1301 |
|
|
2025
Q3 | $1.75M | Sell |
125,059
-86,470
| -41% | -$1.24M | ﹤0.01% | 1188 |
|
|
2025
Q2 | $3.18M | Buy |
211,529
+140,354
| +197% | +$2M | ﹤0.01% | 1064 |
|
|
2025
Q1 | $939K | Sell |
71,175
-1,824
| -2% | -$25.2K | ﹤0.01% | 1339 |
|
|
2024
Q4 | $1.15M | Sell |
72,999
-1,616
| -2% | -$24.3K | ﹤0.01% | 1268 |
|
|
2024
Q3 | $1.19M | Buy |
74,615
+21,340
| +40% | +$343K | ﹤0.01% | 1251 |
|
|
2024
Q2 | $812K | Sell |
53,275
-290,345
| -84% | -$4.16M | ﹤0.01% | 1340 |
|
|
2024
Q1 | $5.04M | Sell |
343,620
-614,880
| -64% | -$8.98M | ﹤0.01% | 921 |
|
|
2023
Q4 | $13.3M | Buy |
958,500
+576,735
| +151% | +$7.71M | 0.01% | 843 |
|
|
2023
Q3 | $5.11M | Buy |
381,765
+327,585
| +605% | +$4.43M | ﹤0.01% | 878 |
|
|
2023
Q2 | $684K | Sell |
54,180
-122,755
| -69% | -$1.43M | ﹤0.01% | 1353 |
|
|
2023
Q1 | $2.01M | Buy |
+176,935
| New | +$1.91M | ﹤0.01% | 1085 |
|
|
2022
Q3 | – | Sell |
-47,945
| Closed | -$531K | – | 1891 |
|
|
2022
Q2 | $531K | Buy |
+47,945
| New | +$521K | ﹤0.01% | 1481 |
|
|
2021
Q4 | – | Sell |
-370,785
| Closed | -$4.81M | – | 1942 |
|
|
2021
Q3 | $4.81M | Sell |
370,785
-281,460
| -43% | -$3.75M | ﹤0.01% | 961 |
|
|
2021
Q2 | $9.54M | Sell |
652,245
-53,780
| -8% | -$752K | 0.01% | 830 |
|
|
2021
Q1 | $8.66M | Buy |
706,025
+43,310
| +7% | +$556K | 0.01% | 846 |
|
|
2020
Q4 | $9.44M | Buy |
662,715
+466,025
| +237% | +$6.28M | 0.01% | 793 |
|
|
2020
Q3 | $2.73M | Buy |
196,690
+147,650
| +301% | +$1.76M | ﹤0.01% | 1005 |
|
|
2020
Q2 | $520K | Buy |
+49,040
| New | +$499K | ﹤0.01% | 1274 |
|
|
2018
Q1 | – | Sell |
-39,065
| Closed | -$293K | – | 1728 |
|
|
2017
Q4 | $293K | Buy |
+39,065
| New | +$281K | ﹤0.01% | 1554 |
|
|
2017
Q3 | – | Sell |
-33,425
| Closed | -$282K | – | 1635 |
|
|
2017
Q2 | $282K | Sell |
33,425
-11,950
| -26% | -$97.2K | ﹤0.01% | 1427 |
|
|
2017
Q1 | $364K | Sell |
45,375
-310
| -0.7% | -$2.68K | ﹤0.01% | 1374 |
|
|
2016
Q4 | $414K | Sell |
45,685
-45,730
| -50% | -$426K | ﹤0.01% | 1333 |
|
|
2016
Q3 | $849K | Buy |
91,415
+7,040
| +8% | +$67.2K | ﹤0.01% | 1141 |
|
|
2016
Q2 | $865K | Hold |
84,375
| – | – | ﹤0.01% | 1126 |
|
|
2016
Q1 | $763K | Sell |
84,375
-162,000
| -66% | -$1.45M | ﹤0.01% | 1157 |
|
|
2015
Q4 | $2.28M | Sell |
246,375
-63,500
| -20% | -$695K | ﹤0.01% | 986 |
|
|
2015
Q3 | $3.96M | Buy |
309,875
+28,000
| +10% | +$348K | 0.01% | 920 |
|
|
2015
Q2 | $3.12M | Hold |
281,875
| – | – | ﹤0.01% | 997 |
|
|
2015
Q1 | $3.22M | Buy |
281,875
+62,875
| +29% | +$667K | ﹤0.01% | 1001 |
|
|
2014
Q4 | $2.21M | Buy |
219,000
+153,500
| +234% | +$1.62M | ﹤0.01% | 1064 |
|
|
2014
Q3 | $688K | Hold |
65,500
| – | – | ﹤0.01% | 1316 |
|
|
2014
Q2 | $565K | Hold |
65,500
| – | – | ﹤0.01% | 1359 |
|
|
2014
Q1 | $575K | Sell |
65,500
-2,500
| -4% | -$21.7K | ﹤0.01% | 1314 |
|
|
2013
Q4 | $558K | Hold |
68,000
| – | – | ﹤0.01% | 1314 |
|
|
2013
Q3 | $514K | Buy |
+68,000
| New | +$495K | ﹤0.01% | 1306 |
|
Other funds holding RDY
AIM
Neuberger Berman Group's RDY Position: Q2 2026 in Review
Neuberger Berman Group reduced its Dr. Reddy's Laboratories (RDY) stake by 51% in Q2 2026, selling an estimated $656K and leaving 45,951 shares worth $666K. The position accounts for ﹤0.01% of the portfolio, ranked #1688.
Neuberger Berman Group first reported a position in RDY in Q3 2013 and has held it in 38 quarters since. The position peaked at $13.3M in Q4 2023. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.
- Neuberger Berman Group held 45,951 shares of Dr. Reddy's Laboratories worth $666K as of Q2 2026.
- Neuberger Berman Group sold 48,591 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $656K.
- Dr. Reddy's Laboratories made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1688 holding.
- Neuberger Berman Group first reported a position in Dr. Reddy's Laboratories in Q3 2013 and has held it in 38 quarters since.
- Neuberger Berman Group's Dr. Reddy's Laboratories position peaked at $13.3M in Q4 2023.
- 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.
Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.